KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancerHumansDiphosphonatesDisease-Free SurvivalNeoplasmsKRAS mutations for codons 12 and 13 were identified in 16/46 (34.7%) of pati ...doi:10.1186/1897-4287-10-S4-A25Julia K Bar...
PCR amplification and DNA sequence analysis or allele-specific PCR for BRAF V600E mutation status are performed on formalin-fixed, paraffin-embedded tissue from the primary tumor or a metastasis. [16] In June 2017, the FDA approved the PRAXIS Extended RAS Panel, next-generation sequencing (...
TheraScreen KRAS kit (Qiagen), a test based on amplification refractory mutation system (ARMS) technology, is the first clinically validated and FDA-approved kit widely used to evaluate tumor-specific mutations in patients with CRC [43]. This kit detects seven mutations in codons 12 and 13 in ...
Currently,determination of tumor gene status for KRAS/RAS and BRAF mutations, as well as HER2 amplifications, are recommended for patients with mCRC. Testing may be carried out for individual genes or as part of a ...
RNA (1 μg) was subjected to reverse transcription (RT), followed by PCR amplification of KRAS, BLT2 and glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) cDNA using an RT-PCR PreMix kit purchased from Intron. The primer sequences used are as follows: human BLT2 (forward, 5′-AGC...
Amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR) for KRAS/NRAS/PIK3CA/BRAF mutations We tested mutations in the KRAS (exons 2, 3 and 4), NRAS (exons 2, 3 and 4), PIK3CA (exon 20) and BRAF (exon 15) genes (mutations detectable with the AmoyDx Kit are detaile...
方法 采用免疫组织化学法(immunohistochemistry,IHC)检测210例CRC患者中4种错配修复(mismatch repair,MMR)蛋白的表达情况;应用荧光多重PCR-毛细管电泳检测MSI的分布情况;应用扩增阻碍突变系统(amplification refractory mutation system,ARMS)-荧光PCR法检测CRC患者KRAS,NRAS基因的突变情况.结果 MMR蛋白表达总缺失率为9.5%(...
KRAS、BRAF基因突变的结直肠癌患者临床病理特征分析 ㊃论著㊃ ＫＲＡＳ㊁ＢＲＡＦ基因突变的结直肠癌患者临床 病理特征分析 刘威１，王菲２，杜洪３，缪娜波３，李旺林１，２，曹杰１，２∗ （１．广州医科大学附属广州市第一人民医院，广州消化疾病中心，结直肠肛门外科，广东广州５１０１８０；２．广州市第...
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Science Signaling. 2011; 4 :166.Little S, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PAW, Smith PD, Cook SJ. Amplification of the driving ...
(TME)5,6. The Cancer Genome Atlas also indicated KRAS mutant colorectal cancer (CRC) are closely associated with decreased immune infiltration and reactivity7. In addition, KRAS inhibition endowed tumors with a remarkable increase in anti-tumor immunity8. Therefore, KRAS mutant tumors are especially...